With a market capitalization (market cap) of $10.2B — a measure of how much the company is worth — Dr. Reddy's Laboratories Limited ranks #916 among the 2,510 companies tracked, and 106th in Healthcare as of October 3, 2026. Shares trade at $12.25, up 0.00% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $10.2B | -12.80% | $12.25 |
| 2025 | Dec 31, 2025 | $11.7B | -11.10% | $14.04 |
| 2024 | Dec 31, 2024 | $13.16B | +13.54% | $15.79 |
| 2023 | Dec 29, 2023 | $11.59B | +34.84% | $13.92 |
Ranking figure $10.2B as of October 3, 2026.
Dr. Reddy's Laboratories Limited's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $12.25 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $10.2B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2026) used a weighted-average 832,405,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
This listing is an ADR. The market cap here is for the U.S. listing we rank; we do not have an ADR ratio, so we do not scale this figure to the parent company's local share count.
Book equity: assets minus liabilities on the latest annual report.
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Not in this snapshot
FY 2026 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2026.
Visit websiteAs of October 3, 2026, Dr. Reddy's Laboratories Limited (RDY) is worth $10.2B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2026, Dr. Reddy's Laboratories Limited’s book equity is about $372.92B. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $10.2B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Dr. Reddy's Laboratories Limited ranks #916 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #106 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| 2022 |
|---|
| Dec 30, 2022 |
| $8.59B |
| -20.80% |
| $10.35 |
| 2021 | Dec 31, 2021 | $10.85B | — | $13.08 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2026
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #913 | Sunoco LP SUN | $10.22B | +0.25% |
| #914 | Dillard's, Inc. DDS | $10.21B | +1.20% |
| #915 | Erie Indemnity Company ERIE | $10.21B | -0.46% |
| #917 | Globus Medical, Inc. GMED | $10.2B | +1.61% |
| #918 | The New York Times Company NYT | $10.18B | -1.59% |
| #919 | Jack Henry & Associates, Inc. JKHY | $10.13B | -0.90% |
Dr. Reddy's Laboratories Limited’s ranking market cap of $10.2B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2026 weighted-average share count of 832,405,000. The historical market-cap series last observed $10.2B on October 2, 2026.
Over the past year, Dr. Reddy's Laboratories Limited’s market cap is down 12.99%, using historical market-cap records rather than today’s share count applied to past prices.
Dr. Reddy's Laboratories Limited (RDY) shares trade at $12.25, up 0.00% on the day, as of October 3, 2026.
Dr. Reddy's Laboratories Limited trades at a live price-to-earnings (P/E) ratio of 0.2, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.